MO · Earnings call · 2026Q3T · Full report

Regulatory Risk

ALTRIA GROUP, INC. · 2026-10-29 · Importance 52 · Surprise 42 · In source text

Altria said FDA enforcement guidance had allowed Helix to move through the regulatory process more efficiently, but warned that guidance can change. Helix and NJOY filed a complaint against the FDA during the quarter, seeking a review process that meets Congress’s 180-day statutory timeframe and permission for products with applications pending beyond that period to remain on the market while a new process is established. After the filing, the FDA announced plans to evaluate changes to the PMTA framework and pursue new rulemaking, citing implementation challenges with its 2021 PMTA rule, illicit-market growth and slow product authorizations. Management also said consistent federal, state and local enforcement against illicit e-vapor products is needed alongside a more efficient authorization process.

Key facts

• Helix and NJOY filed legal action against the FDA during Q3 2026 seeking a review process meeting Congress's 180-day timeframe and permission for products with applications pending beyond that timeframe to remain on the market while a new process is established.
• The FDA announced plans to evaluate changes to the PMTA framework and pursue new rulemaking.

Impact estimates